

Abstract of the Disclosure

5 The present invention concerns compositions comprising an IL-1 mutein that is useful as an adjuvant for stimulating a controlled immune response when administered to a human or animal. For example, muteins of IL-1 β can be used according to the invention. The mutein composition can include a vaccine antigen, such as whole inactivated or attenuated virus, recombinant or synthetic peptides, and other antigenic materials.

 The present invention also pertains to the use of an IL-1 mutein in a human or animal as an adjuvant to increase immune responses to an antigen or other material to which an immune response is desired.